samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > a new age for biotechnology - 18th to 19th june 2001, london
PUBLICATIONS
European Biopharmaceutical Review

A New Age for Biotechnology - 18th to 19th June 2001, London

The financing and business environment for biotechnology in Europe was very much the theme of this two-day conference run by Marcus Evans in London in June. Following introductory comments by the first day's Chairman, Nick Woolf, Biotech Analyst at ABN Amro, the conference kicked off with an overview of the latest developments from Shawn Cross, Vice President Healthcare Investment Banking at Deutsche Bank. Shaun described the peaks and troughs of biotech valuation cycles over the last four to five years and the pattern of IPOs in the sector before the peak of 2000. All agreed that 2000 had been a stellar year and no-one should expect a repeat any time soon. However, activity levels and investor interest were presented as having stabilised following the slump at the beginning of this year, and private equity firms were described as still favourably disposed towards biotech investment. Finally, PIPEs (private investment in public equity) were presented as having come of age in the current environment, as a popular financing tool for biotechs to consider. The advantages listed were their speed and lower costs as a means to raise funds without the time out on the road. The disadvantages were listed to include the dilution effect for the existing shareholders and the discounts at which private buyers could access the shares.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New study confirms that purity and type of coating biomaterials used in 2D cell culturing are crucial for efficient stem cell proliferation

Rousselot®, Darling Ingredients’ health brand and the global leader1 of collagen-based solutions, revealed the results of a new study which demonstrates that Rousselot’s ultra-pure GMP-grade2 gelatins outperformed standard non-endotoxin purified research grade gelatins and other coating materials in 2D cell culturing. Data demonstrate that endotoxin (lipopolysaccharide, LPS) levels and the nature of biomaterials used in cell coating have a significant impact on cell morphology and proliferation.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement